Genentech, Inc.

Merck Canada Inc.

Xenon Pharmaceuticals Inc.

Jean-Philippe Leclerc

Ramsay Beveridge

Alexandre Lemire

Daniel P Sutherlin

Oscar Miguel Moradei

Chun Sing Li

Claudio F Sturino

Kwong Wah Lai

Steven McKerrall

Nicolas Lachance

Liang Zhao

Jacob Bradley Schwarz

Wendy Lee

Georgette M Castanedo

Birong Zhang

Nicole Blaquiere

Paul Gibbons

Michael Scott Wilson

Yeeman K Ramtohul

Cuong Q Ly

Marie-Gabrielle Braun

Joachim Rudolph

Philippe Bergeron

Zhiguo Liu

Wenfeng Liu

Leo Fu

Chun-Sing Li

Nicole Alice Blaquiere

Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Phenoxy-pyridyl-pyrimidine compounds and methods of use

The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain. The following compound is illustrative: 

Therapeutic compounds and methods of use thereof

The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y&#x2014;Y, R, R, R, R, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. 

Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase

Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. 

Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Growing community of inventors

Laval, Canada

Jean-Philippe Leclerc